RayKnowChina Research Map
Shortlist0

TianjinTianjin Medical University

Tianjin Medical University General Hospital

天津医科大学总医院

Listed for 29 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

Official links opened and checked on 2026-11-08.

Getting in touch

Research at Tianjin Medical University General Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌1 paper led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌5 papers led
  3. Hepatocellular carcinoma肝细胞癌22 papers led
  4. Stomach cancer胃癌30 papers led
  5. Hepatoblastoma肝母细胞瘤1 paper led
  6. Retinoblastoma视网膜母细胞瘤1 paper led
  7. Osteosarcoma骨肉瘤3 papers led
  8. Gastrointestinal stromal tumour胃肠道间质瘤2 papers led
  9. Neuroblastoma神经母细胞瘤0 papers led
  10. Multiple myeloma多发性骨髓瘤27 papers led1 open trial led
  11. B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病0 papers led1 open trial led
  12. Aplastic anaemia再生障碍性贫血23 papers led
  13. Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜1 paper led
  14. Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病22 papers led2 open trials led
  15. IgG4-related diseaseIgG4相关性疾病3 papers led
  16. Myasthenia gravis重症肌无力21 papers led1 open trial led
  17. Moyamoya disease烟雾病2 papers led
  18. Idiopathic pulmonary fibrosis特发性肺纤维化7 papers led
  19. Amyotrophic lateral sclerosis肌萎缩侧索硬化症1 paper led
  20. Spinal muscular atrophy脊髓性肌萎缩症1 paper led
  21. Duchenne muscular dystrophy杜氏肌营养不良2 papers led
  22. Alport syndromeAlport 综合征1 paper led
  23. IgA nephropathyIgA 肾病10 papers led
  24. Osteogenesis imperfecta成骨不全症4 papers led
  25. Primary biliary cholangitis原发性胆汁性胆管炎7 papers led
  26. Primary sclerosing cholangitis原发性硬化性胆管炎1 paper led
  27. Hirschsprung disease先天性巨结肠0 papers led
  28. Familial adenomatous polyposis家族性腺瘤性息肉病0 papers led
  29. Leber hereditary optic neuropathyLeber 遗传性视神经病变3 papers led

Not listed for: Chordoma, Ewing sarcoma, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Fanconi anaemia, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Fabry disease, Pompe disease, Behçet disease, Gaucher disease, Niemann–Pick disease type C, Congenital diaphragmatic hernia, Inherited epidermolysis bullosa, Hereditary angioedema, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 1 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.04%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

2 hospitals in Tianjin for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
    Phase
    Phase 2
    Started
    2024-01
    Registry
    NCT05956587

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesChongqing, Fuzhou, Guangzhou, Hangzhou, Linyi, Liuzhou, Nanchang, Tianjin, Wuhan, Xi'an, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImaging & AI
Departments in papersENT / head & neck surgery

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 5 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 2220242025: 112025

2 hospitals in Tianjin for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesMolecular markers & genomicsImaging & AISurgery
Departments in papersGastroenterology / hepatology

Over half of these papers are lab or animal studies.

Papers it led5
  1. Innovative role of the antidepressant imipramine in esophageal squamous cell carcinoma treatment: Promoting apoptosis and protective autophagy.2025International immunopharmacology
  2. Single-cell sequencing analysis reveals cancer-associated pericyte subgroup in esophageal squamous cell carcinoma to predict prognosis.2024Frontiers in immunologyFree full text
  3. Early-onset esophageal squamous cell carcinoma with achalasia: A case report.2024MedicineFree full text
  4. Transgelin promotes ferroptosis to inhibit the malignant progression of esophageal squamous cell carcinoma.2023International journal of oncologyFree full text
  5. Mig-6 could inhibit cell proliferation and induce apoptosis in esophageal squamous cell carcinoma.2022Thoracic cancerFree full text
Chinese-language papers (not in the count)1
  1. [Ferroptosis suppressor genes are highly expressed in esophageal cancer to inhibit tumor cell ferroptosis].2024Nan fang yi ke da xue xue bao = Journal of Southern Medical UniversityFree full text
All its trials on ClinicalTrials.gov, any status2
  1. Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell CarcinomaTerminatedNCT05461794Study sitePhase 2Start 2022-10
  2. A Study of CS1001 in Subjects With Esophageal Squamous Cell CarcinomaCompletedNCT04187352Study sitePhase 3Start 2019-12
More papers found outside PubMed (not counted)12
  1. 305P Safety and efficacy of endoscopic resection followed by adjuvant chemoradiotherapy (ERACT) for organ preservation in early-stage oesophageal squamous cell carcinoma with high-risk features: A prospective, multicenter, phase II clinical2025Annals of Oncologyarticle
  2. 1426P BL-B01D1, an EGFR x her3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC)2024Annals of Oncologyarticle
  3. Additional file 10 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figsharedataset
  4. Additional file 11 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figsharedataset
  5. Additional file 12 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figsharedataset
  6. Additional file 13 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figsharedataset
  7. Additional file 14 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figsharedataset
  8. Additional file 15 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figsharedataset
  9. Additional file 9 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figsharedataset
  10. RETRACTED ARTICLE: Tumor-associated fibroblasts derived exosomes induce the proliferation and cisplatin resistance in esophageal squamous cell carcinoma cells through RIG-I/IFN-β signaling2022Figsharedataset
  11. 166TiP Pembrolizumab combined with neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy followed surgery for locally advanced esophageal squamous cell carcinoma: Protocol for a multi-center, prospective, randomized-controlled, phas2021Annals of Oncologyarticle
  12. A Novel Potential Diagnostic and Prognostic Biomarker for Esophageal Cancer2021Research Squarepreprint

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 22 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
22
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 6620212022: 5520222023: 2220232024: 6620242025: 222025

4 hospitals in Tianjin for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

No open trial on hepatocellular carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesRecurrence & prognosisImmunotherapy & targeted drugsImaging, AI & early detection
Departments in papersSurgery (general/hepatobiliary/pancreatic)Pathology / laboratory medicineNeurosurgeryGastroenterology / hepatology

Over half of these papers are lab or animal studies.

Papers it led22
  1. DNASE1L3 regulates macrophage polarization through the NLRP3-GSDMD signaling pathway affecting hepatocellular carcinoma progression.2026Molecular biology of the cell
  2. Biomimetic Nanoparticles with Dual Targeting for Hepatocellular Carcinoma Promote Tumor Immune System Activation by Enhancing Extracellular ATP Homeostasis.2025ACS applied materials & interfaces
  3. LI-RADS for diagnosing hepatocellular carcinoma by contrast-enhanced US with SonoVue and Sonazoid-a single center prospective study.2025Abdominal radiology (New York)
  4. Retrospective Analysis of Aberrant Hepatic Artery in 1250 Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization.2024Annali italiani di chirurgia
  5. Identification of a vascular invasion-related signature based on lncRNA pairs for predicting prognosis in hepatocellular carcinoma.2024BMC gastroenterologyFree full text
  6. Overexpression of NDRG1 leads to poor prognosis in hepatocellular carcinoma through mediating immune infiltration and EMT.2024Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  7. Identification of SPP1 + macrophages as an immune suppressor in hepatocellular carcinoma using single-cell and bulk transcriptomics.2024Frontiers in immunologyFree full text
  8. Luteolin exerts anti-tumour immunity in hepatocellular carcinoma by accelerating CD8+ T lymphocyte infiltration.2024Journal of cellular and molecular medicineFree full text
  9. Nrf2/ASPM axis regulated vasculogenic mimicry formation in hepatocellular carcinoma under hypoxia.2024Journal of gastroenterology
  10. LOXL2 serves as a prognostic biomarker for hepatocellular carcinoma by mediating immune infiltration and vasculogenic mimicry.2023Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  11. Interleukin-35 expression promotes hepatocellular carcinogenesis by inducing γδ T-cell exhaustion.2023Genomics
  12. Four-Pyroptosis Gene-Based Nomogram as a Novel Strategy for Predicting the Effect of Immunotherapy in Hepatocellular Carcinoma.2022BioMed research internationalFree full text
  13. Deoxyribonuclease 1-like 3 Inhibits Hepatocellular Carcinoma Progression by Inducing Apoptosis and Reprogramming Glucose Metabolism.2022International journal of biological sciencesFree full text
  14. LncRNA n339260 functions in hepatocellular carcinoma progression via regulation of miRNA30e-5p/TP53INP1 expression.2022Journal of gastroenterology
  15. γδ T cells: The potential role in liver disease and implications for cancer immunotherapy.2022Journal of leukocyte biology
  16. Elevated expression of the MYB proto-oncogene like 2 (MYBL2)-encoding gene as a prognostic and predictive biomarker in human cancers.2022Mathematical biosciences and engineering : MBE
  17. DNASE1L3 arrests tumor angiogenesis by impairing the senescence-associated secretory phenotype in response to stress.2021AgingFree full text
  18. The role of different PI3K protein subtypes in the metastasis, angiogenesis and clinical prognosis of hepatocellular carcinoma.2021Annals of diagnostic pathology
  19. Long noncoding RNA TP53TG1 suppresses the growth and metastasis of hepatocellular carcinoma by regulating the PRDX4/β-catenin pathway.2021Cancer letters
  20. Pan-cancer analysis indicates that MYBL2 is associated with the prognosis and immunotherapy of multiple cancers as an oncogene.2021Cell cycle (Georgetown, Tex.)Free full text
  21. CircANKRD52 Promotes the Tumorigenesis of Hepatocellular Carcinoma by Sponging miR-497-5p and Upregulating BIRC5 Expression.2021Cell transplantationFree full text
  22. Interleukin-35 has a tumor-promoting role in hepatocellular carcinoma.2021Clinical and experimental immunology

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 30 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.3%.

Papers led
30
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 9920212022: 4420222023: 5520232024: 4420242025: 772025

3 hospitals in Tianjin for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
    Phase
    Phase 3
    Started
    2025-05
    Registry
    NCT06901531

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Shanghai, Shijiazhuang, Tianjin, Wuhan, Zhengzhou

  2. Recruiting
    A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor
    Phase
    Phase 1
    Started
    2022-02
    Registry
    NCT05262491

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Chengdu, Hangzhou, Jinan, Nanchang, Tianjin

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImaging & AIPeritoneal spread & advanced diseaseSurgery
Departments in papersSurgery (general/hepatobiliary/pancreatic)Gastroenterology / hepatologyRadiology / nuclear medicineRheumatology & immunology
Papers it led30
  1. CircFoxo3 knockdown inhibit gastric cancer progression by regulating Foxo3.2026In vitro cellular & developmental biology. Animal
  2. In Silico Identification and Verification of the Anticancer Mechanism of TMBM-010 from Oxytropis herba with a Rational Delivery System Design.2025ACS applied bio materials
  3. Identification of prognostic indicators for early recurrence of gastric cancer following laparoscopic gastrectomy.2025BMC surgeryFree full text
  4. Tumor-Derived EBI3 Promotes CD8+ T-cell Exhaustion via STAT4-IL10/CCL5 in Gastric Cancer.2025Cancer immunology research
  5. Targeting Tumor Differentiation Grade-related Genes Prognostic Signature Including COL5A1 Based on Single-cell RNA-seq in Gastric Cancer.2025International journal of medical sciencesFree full text
  6. Potential Role of EBI3 in Gastric Cancer and Its Inductive Effects on T-Cell Exhaustion.2025Journal of the American College of Surgeons
  7. Efficacy analysis of modified double band ligation-assisted endoscopic submucosal resection and endoscopic mucosal dissection in the treatment of gastric gastrointestinal stromal tumors (≤ 1.5 cm).2025Surgical endoscopy
  8. RGS4 promotes the progression of gastric cancer through the focal adhesion kinase/phosphatidyl-inositol-3-kinase/protein kinase B pathway and epithelial-mesenchymal transition.2025World journal of gastroenterologyFree full text
  9. Prognostic significance of lymphovascular invasion in pN0 stage gastric cancer: a propensity score matching analysis.2024BMC surgeryFree full text
  10. A competing-risk nomogram for predicting gastric cancer-specific survival in patients over 70 years: A SEER-based study.2024Cancer epidemiology
  11. Comparison of SOX and CAPOX in patients with advanced gastric cancer after laparoscopic D2 gastrectomy: A randomized controlled trial.2024Cancer medicineRCTFree full text
  12. Construction of store-operated calcium entry-related gene signature for predicting prognosis and indicates immune microenvironment infiltration in stomach adenocarcinomas.2024Scientific reportsFree full text
  13. Different Methods of Minimally Invasive Esophagojejunostomy After Total Gastrectomy for Gastric Cancer: Outcomes from Two Experienced Centers.2023Annals of surgical oncologyFree full text
  14. Relationship between histone demethylase LSD family and development and prognosis of gastric cancer.2023Frontiers in immunologyFree full text
  15. Prognostic value and immunological roles of GPX3 in gastric cancer.2023International journal of medical sciencesFree full text
  16. Efficacy of endoscopic ultrasound and endoscopic resection for esophageal schwannoma.2023Scandinavian journal of gastroenterology
  17. SMPDL3B contributes to gastric adenocarcinoma cells progression by promoting the infiltration of M2 macrophages.2023Turkish journal of medical sciencesFree full text
  18. Genetic mutation and tumor microbiota determine heterogenicity of tumor immune signature: Evidence from gastric and colorectal synchronous cancers.2022Frontiers in immunologyFree full text
  19. Comprehensive analysis to identify pseudogenes/lncRNAs-hsa-miR-200b-3p-COL5A2 network as a prognostic biomarker in gastric cancer.2022HereditasFree full text
  20. CD40×HER2 bispecific antibody overcomes the CCL2-induced trastuzumab resistance in HER2-positive gastric cancer.2022Journal for immunotherapy of cancerFree full text
  21. Temporal heterogeneity of HER2 expression in metastatic gastric cancer: a case report.2022World journal of surgical oncologyFree full text
  22. Impact of Neoadjuvant Therapy on Minimally Invasive Surgical Outcomes in Advanced Gastric Cancer: An International Propensity Score-Matched Study.2021Annals of surgical oncology
  23. A novel ferroptosis-related lncRNA signature for prognosis prediction in gastric cancer.2021BMC cancerFree full text
  24. Construction and Validation of a Nomogram for the Preoperative Prediction of Lymph Node Metastasis in Gastric Cancer.2021Cancer control : journal of the Moffitt Cancer CenterFree full text
  25. RAI14 Regulated by circNFATC3/miR-23b-3p axis Facilitates Cell Growth and Invasion in Gastric Cancer.2021Cell transplantationFree full text
  26. A comprehensive update on early gastric cancer: defining terms, etiology, and alarming risk factors.2021Expert review of gastroenterology & hepatology
  27. The Potential Role of REG Family Proteins in Inflammatory and Inflammation-Associated Diseases of the Gastrointestinal Tract.2021International journal of molecular sciencesFree full text
  28. Cronkhite-Canada syndrome: An investigation in clinical features and pathogenesis.2021Journal of digestive diseases
  29. Ectopic insulinoma diagnosed by 68Ga-Exendin-4 PET/CT: A case report and review of literature.2021MedicineFree full text
  30. Primary hepatic squamous carcinoma concurrent with gastric signet ring cell carcinoma demonstrated by 18F-fluorodeoxyglucose positron emission tomography/computed tomography.2021The Korean journal of internal medicineFree full text
All its trials on ClinicalTrials.gov, any status9
  1. A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric CancerRecruitingNCT06901531Study sitePhase 3Start 2025-05
  2. A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid TumorRecruitingNCT05262491Study sitePhase 1Start 2022-02
  3. A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal CancersActive, not recruitingNCT05152147Study sitePhase 3Start 2021-12
  4. A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior TreatmentTerminatedNCT04178460Study sitePhase 1Start 2020-02
  5. A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer DiagnosisStatus unknownNCT04440605Study siteStart 2020-07
  6. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric CancerStatus unknownNCT04486651Study sitePhase 3Start 2020-09
  7. Study of Faecal Bacteria Detection in Early Screening and Diagnosis of GCStatus unknownNCT04638959Study siteStart 2019-09
  8. Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)Status unknownNCT02461407Study sitePhase 2/Phase 3Start 2015-06
  9. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric CancerCompletedNCT01839500Study siteStart 2013-04

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatoblastoma

肝母细胞瘤

Led 1 of the 154 English-language PubMed papers on hepatoblastoma with an author in mainland China, 2021–2025: 0.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

4 hospitals in Tianjin for hepatoblastoma88 hospitals in China for hepatoblastoma

No open trial on hepatoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led 1 of the 301 English-language PubMed papers on retinoblastoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

3 hospitals in Tianjin for retinoblastoma196 hospitals in China for retinoblastoma

No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 3 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 1120242025: 002025

15 hospitals in Tianjin for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 2 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.4%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

6 hospitals in Tianjin for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatology

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led no English-language PubMed papers on neuroblastoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

11 hospitals in Tianjin for neuroblastoma352 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Neuroprotective effects of fingolimod in mouse models of Parkinson's disease.2017FASEB journal : official publication of the Federation of American Societies for Experimental Biology

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 27 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 1.6%.

Papers led
27
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
4
led by another institution
Papers led per year
2021: 4420212022: 5520222023: 7720232024: 2220242025: 882025

5 hospitals in Tianjin for multiple myeloma178 hospitals in China for multiple myeloma

Open trials with this hospital 5

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors
    Phase
    Phase 1/Phase 2
    Started
    2024-11
    Registry
    NCT06911710

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin Medical University General HospitalTianjin

  2. Recruiting
    A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2024-07
    Registry
    NCT06083207

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Nanjing, Nanning, Shanghai, Suzhou, Tianjin, Wuhan, Xi'an, Xuzhou

  3. Recruiting
    Long-term Follow-up Registry Study of Equecabtagene Autoleucel Injection
    Phase
    Not given
    Started
    2024-12
    Registry
    NCT07028970

    Age not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Tianjin, Wuhan, Zhengzhou

  4. Recruiting
    Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma
    Phase
    Phase 2
    Started
    2022-04
    Registry
    NCT05294055

    Age 18 years to 65 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 6 listed hospitals as study sitesBeijing, Hefei, Jinan, Tianjin, Zhengzhou

  5. Recruiting
    A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2021-09
    Registry
    NCT04973605

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changsha, Chongqing, Fuzhou, Hangzhou, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xiamen, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesBispecific & antibody drugsDiagnosis, MRD & riskStem cell transplant
Papers it led27
  1. Osteoblasts inhibit NK cell killing function via RANK/RANKL in multiple myeloma.2026Journal of investigative medicine : the official publication of the American Federation for Clinical Research
  2. Combining PIM-2 and PARP1 Inhibitors Induces MICA Expression on Multiple Myeloma Cells to Activate NK Cells through NKG2D Binding.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  3. Targets Selection for Precision Therapy of Relapsed/Refractory Multiple Myeloma: the Latest Advancements.2025Current treatment options in oncology
  4. Kaempferol induces mitophagy and disrupts iron metabolism via SFXN2 leading to apoptosis in multiple myeloma cells.2025Free radical biology & medicine
  5. Enhancing antitumor immunity via ROS-ERS and pyroptosis-induced immunogenic cell death in multiple myeloma.2025Journal for immunotherapy of cancerFree full text
  6. T-lymphocytes suppression by CD14+ monocytes with high expression of ULK2 in patients with multiple myeloma.2025Journal of translational medicineFree full text
  7. Complement C3a promotes the formation of osteoclasts by inhibiting Sirt1 to activate the PI3K/PDK1/SGK3 pathway in patients with multiple myeloma.2025Journal of translational medicineFree full text
  8. Antitumor effect of BC12-3 on multiple myeloma via proteasome inhibition.2025Medical oncology (Northwood, London, England)
  9. A case of acute myeloid leukemia and multiple myeloma is observed to occur simultaneously.2025MedicineFree full text
  10. Targeting NKG2D/NKG2DL axis in multiple myeloma therapy.2024Cytokine & growth factor reviews
  11. Immune profiles to predict bortezomib-based treatment response for multiple myeloma patients.2024International immunopharmacology
  12. BSA-AIE Nanoparticles with Boosted ROS Generation for Immunogenic Cell Death Immunotherapy of Multiple Myeloma.2023Advanced materials (Deerfield Beach, Fla.)
  13. Gene therapy with B-cell maturation antigen/CD3 bispecific antibody encoding plasmid DNA for treating multiple myeloma.2023British journal of haematology
  14. An overview of pim kinase as a target in multiple myeloma.2023Cancer medicineFree full text
  15. Bone marrow-derived mesenchymal stem cells inhibit NK cell function via Tim-3/galectin-9 in multiple myeloma patients.2023Clinical and translational medicineFree full text
  16. Therapeutic strategies to enhance immune response induced by multiple myeloma cells.2023Frontiers in immunologyFree full text
  17. Cellular immunity in the era of modern multiple myeloma therapy.2023International journal of cancer
  18. Study on the Effect of EZH2 Inhibitor Combined with TIGIT Monoclonal Antibody against Multiple Myeloma Cells.2023International journal of molecular sciencesFree full text
  19. Tumor-associated macrophages regulate the function of cytotoxic T lymphocyte through PD-1/PD-L1 pathway in multiple myeloma.2022Cancer medicineFree full text
  20. CD155/TIGIT signalling plays a vital role in the regulation of bone marrow mesenchymal stem cell-induced natural killer-cell exhaustion in multiple myeloma.2022Clinical and translational medicineFree full text
  21. Malignant plasmacytes in bone marrow detected by flow cytometry as a predictor for the risk stratification system of multiple myeloma.2022Cytometry. Part B, Clinical cytometry
  22. Roles of LINC01473 and CD74 in osteoblasts in multiple myeloma bone disease.2022Journal of investigative medicine : the official publication of the American Federation for Clinical ResearchFree full text
  23. Effect of clinical application of anti-CD38 and anti-CD47 monoclonal antibodies on blood group detection and transfusion therapy and treatment.2022Leukemia research
  24. Bone marrow-derived mesenchymal stem cells inhibit CD8+ T cell immune responses via PD-1/PD-L1 pathway in multiple myeloma.2021Clinical and experimental immunology
  25. Predictive Role of Immune Profiling for Survival of Multiple Myeloma Patients.2021Frontiers in immunologyFree full text
  26. Review: Effects of anti-CD38 monoclonal antibodies on red blood cell transfusion and interventions.2021Journal of clinical laboratory analysisFree full text
  27. lncRNA MSTRG.29039.1 Promotes Proliferation by Sponging hsa-miR-12119 via JAK2/STAT3 Pathway in Multiple Myeloma.2021Oxidative medicine and cellular longevityFree full text
All its trials on ClinicalTrials.gov, any status16
  1. The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic TumorsRecruitingNCT06911710Lead sponsorPhase 1/Phase 2Start 2024-11
  2. Long-term Follow-up Registry Study of Equecabtagene Autoleucel InjectionRecruitingNCT07028970Study siteStart 2024-12
  3. A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple MyelomaRecruitingNCT06083207Study sitePhase 1/Phase 2Start 2024-07
  4. Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and LymphomaRecruitingNCT05294055Study sitePhase 2Start 2022-04
  5. A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple MyelomaRecruitingNCT04973605Study sitePhase 1/Phase 2Start 2021-09
  6. Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT06158841Study sitePhase 3Start 2024-05
  7. A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)Active, not recruitingNCT06464991Study sitePhase 3Start 2024-03
  8. A Study of NINLARO® in Chinese Adults With Multiple MyelomaActive, not recruitingNCT05013190Study siteStart 2021-10
  9. A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)CompletedNCT04939142Study sitePhase 3Start 2021-07
  10. A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT05083169Study sitePhase 3Start 2021-10
  11. A Study of Ninlaro in Real World Clinical Practice in ChinaCompletedNCT04328662Study siteStart 2020-05
  12. Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)Status unknownNCT03975907Study sitePhase 1/Phase 2Start 2019-06
  13. TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT03860038Study sitePhase 2Start 2019-01
  14. TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT03952091Study sitePhase 3Start 2019-03
  15. Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple MyelomaCompletedNCT03029234Study sitePhase 3Start 2017-03
  16. A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT03234972Study sitePhase 3Start 2017-11

Run the PubMed searchClinicalTrials.gov

Blood disorders

B-cell acute lymphoblastic leukaemia

B 细胞急性淋巴细胞白血病

Led no English-language PubMed papers on B-cell acute lymphoblastic leukaemia in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Tianjin for B-cell acute lymphoblastic leukaemia90 hospitals in China for B-cell acute lymphoblastic leukaemia

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors
    Phase
    Phase 1/Phase 2
    Started
    2024-11
    Registry
    NCT06911710

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin Medical University General HospitalTianjin

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic TumorsRecruitingNCT06911710Lead sponsorPhase 1/Phase 2Start 2024-11

Run the PubMed searchClinicalTrials.gov

Blood disorders

Aplastic anaemia

再生障碍性贫血

Led 23 of the 412 English-language PubMed papers on aplastic anaemia with an author in mainland China, 2021–2025: 5.6%.

Papers led
23
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 5520212022: 9920222023: 4420232024: 2220242025: 332025

2 hospitals in Tianjin for aplastic anaemia63 hospitals in China for aplastic anaemia

No open trial on aplastic anaemia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesImmunosuppressive treatmentChildrenStem cell transplant
Papers it led23
  1. From severe aplastic anemia with TERT variant to Wilson disease - associations or not.2025Annals of hematologyFree full text
  2. Multi-omics analysis links NFKB1 activation to poor immunosuppressive therapy response in acquired aplastic anemia.2025Hematology (Amsterdam, Netherlands)
  3. Role of Macrophage TLR4 Expression in the Immunopathogenesis of Severe Aplastic Anemia.2025Journal of clinical laboratory analysisFree full text
  4. Dioscin alleviates aplastic anemia through regulatory T cells promotion.2024Hematology (Amsterdam, Netherlands)
  5. HERVs may perform as the initial trigger for acquired aplastic anemia.2024Journal of translational medicineFree full text
  6. Molecular mechanisms underlying the role of HLA-DQ in systemic immune activation in severe aplastic anemia.2023Blood cells, molecules & diseases
  7. Partial SAA patients benefit from delayed response of IST.2023Frontiers in immunologyFree full text
  8. The effectiveness of a novel treatment of TIM-3(-) NK cells infusion in murine models of immune-mediated bone marrow failure.2023Journal of clinical laboratory analysisFree full text
  9. Traditional Chinese medicine for treating aplastic anemia.2023Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiquesFree full text
  10. Single-cell transcriptomic analysis of PB and BM NK cells from severe aplastic anaemia patients.2022Clinical and translational medicineFree full text
  11. New Trends in Nontransplant Therapy for Acquired Aplastic Anemia.2022Current pharmaceutical design
  12. Abnormal Proteomics Profile of Plasma Reveals the Immunological Pathogenesis of Severe Aplastic Anemia.2022Disease markersFree full text
  13. Dioscin Regulating Bone Marrow Apoptosis in Aplastic Anemia.2022Drug design, development and therapyFree full text
  14. A mouse model of irradiation and spleen-thymus lymphocyte infusion induced aplastic anemia.2022Hematology (Amsterdam, Netherlands)
  15. Cofilin-1 participates in the hyperfunction of myeloid dendritic cells in patients with severe aplastic anaemia.2022Journal of cellular and molecular medicineFree full text
  16. Bone marrow free immune checkpoints as a potential biomarker for differential diagnosis of acquired bone marrow failures.2022Journal of clinical laboratory analysisFree full text
  17. Identification of potential pathogenic genes for severe aplastic anemia by whole-exome sequencing.2022Journal of clinical laboratory analysisFree full text
  18. Abnormal expression of histone acetylases in CD8+ T cells of patients with severe aplastic anemia.2022Journal of clinical laboratory analysisFree full text
  19. Expression and function of SLAMF6 in CD8+ T lymphocytes of patients with severe aplastic anemia.2021Cellular immunology
  20. Clinical study on empirical and diagnostic-driven (pre-emptive) therapy of voriconazole in severe aplastic anaemia patients with invasive fungal disease after intensive immunosuppressive therapy.2021European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical MicrobiologyRCT
  21. Upregulated Expression of Profilin1 on Dendritic Cells in Patients With Severe Aplastic Anemia.2021Frontiers in immunologyFree full text
  22. Myeloid dendritic cells in severe aplastic anemia patients exhibit stronger phagocytosis.2021Journal of clinical laboratory analysisFree full text
  23. Relationship between immune status after ATG treatment and PNH clone evolution in patients with severe aplastic anemia.2021Journal of clinical laboratory analysisFree full text
Chinese-language papers (not in the count)11
  1. [Glucose-regulated protein 78 regulates endoplasmic reticulum stress in the pathogenesis of aplastic anemia].2025Zhonghua yi xue za zhi
  2. [Immune related pancytopenia: a new type of bone marrow failure].2025Zhonghua yi xue za zhi
  3. [Research progress on the pathogenesis of acquired aplastic anemia].2024Zhonghua nei ke za zhi
  4. [How to think about the clinical classifications of acquired aplastic anemia].2024Zhonghua yi xue za zhi
  5. [Interpretiation of guidelines for the diagnosis and management of aplastic anemia in China (2022)].2023Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  6. [The expression and correlation analysis of TOX and inhibitory receptors on peripheral blood CD8+T cells in patients with aplastic anemia].2023Zhonghua yi xue za zhi
  7. [Abnormal expression of CXCR5+CD8+ T cells and CXCL13 in severe aplastic anemia patients and their correlation with hematological parameters].2023Zhonghua yi xue za zhi
  8. [Exclusive diagnosis of aplastic anemia].2022Zhonghua yi xue za zhi
  9. [Research Progress on Pathogenesis of Congenital Pure Red Cell Aplasia---Review].2021Zhongguo shi yan xue ye xue za zhi
  10. [Study on the loss of HLA-A allele expression in patients with aplastic anemia].2021Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  11. [Immune regulatory effect of tacrolimus in patients with severe aplastic anemia and in murine model].2021Zhonghua yi xue za zhi
All its trials on ClinicalTrials.gov, any status1
  1. Efficacy and Safety of Thrombopoietin In Patients With Severe and Very Severe Aplastic AnemiaStatus unknownNCT02857530Lead sponsorPhase 2Start 2016-08

Run the PubMed searchClinicalTrials.gov

Blood disorders

Thrombotic thrombocytopenic purpura

血栓性血小板减少性紫癜

Led 1 of the 64 English-language PubMed papers on thrombotic thrombocytopenic purpura with an author in mainland China, 2021–2025: 1.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

3 hospitals in Tianjin for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura

No open trial on thrombotic thrombocytopenic purpura lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurosurgery
Papers it led1
  1. Molecular basis of thrombotic microangiopathy.2025Journal of thrombosis and haemostasis : JTH

Run the PubMed searchClinicalTrials.gov

Other diseases

Neuromyelitis optica spectrum disorder

视神经脊髓炎谱系疾病

Led 22 of the 485 English-language PubMed papers on neuromyelitis optica spectrum disorder with an author in mainland China, 2021–2025: 4.5%.

Papers led
22
2021–2025
Trials led
12
any status, ClinicalTrials.gov
Open trials led
2
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 6620212022: 0020222023: 5520232024: 3320242025: 772025

2 hospitals in Tianjin for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder

Open trials with this hospital 4

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder
    Phase
    Phase 3
    Started
    2026-01
    Registry
    NCT07420296

    Age 18 years to 80 years (registered criteria)

    Led by Tianjin Medical University General HospitalTianjin

  2. Recruiting
    Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases
    Phase
    Phase 1/Phase 2
    Started
    2025-04
    Registry
    NCT07022197

    Age 18 years to 60 years (registered criteria)

    Led by Tianjin Medical University General HospitalTianjin

  3. Recruiting
    A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
    Phase
    Phase 2/Phase 3
    Started
    2024-07
    Registry
    NCT06413654

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiamen, Zhengzhou

  4. Recruiting
    Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD)
    Phase
    Early phase 1
    Started
    2022-04
    Registry
    NCT05145361

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Taiyuan, Tianjin, Xi'an

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesAntibodies & diagnosisBiologic drugsImaging
Departments in papersNeurologyRadiology / nuclear medicine
Papers it led22
  1. A real-world comparative study on the efficacy and safety of tocilizumab and rituximab in patients with neuromyelitis optica spectrum disease and myelin oligodendrocyte glycoprotein antibody-associated disease.2026Multiple sclerosis and related disorders
  2. Type I Interferon Signaling Augments Autoimmunity in Neuromyelitis Optica Spectrum Disorder.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  3. Changes in T lymphocyte subsets in patients with acute neuromyelitis optica spectrum disorder.2025Frontiers in immunologyFree full text
  4. Astrocytes and microglia in multiple sclerosis and neuromyelitis optica.2025Handbook of clinical neurology
  5. Ofatumumab treatment in patients with neuromyelitis optica spectrum disorder: a retrospective multicenter cohort study.2025Journal of neurology
  6. Effectiveness and safety of glucocorticoids bridging rituximab in neuromyelitis spectrum disorder.2025Multiple sclerosis and related disorders
  7. Elevated levels of cerebrospinal fluid CHIT1 correlate with disease activity in neuromyelitis optica spectrum disorder.2025Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  8. Early versus escalation treatment of tocilizumab in neuromyelitis optica spectrum disorder: a retrospective study.2025Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  9. 4-Octyl itaconate inhibits inflammation via the NLRP3 pathway in neuromyelitis optica spectrum disorders.2024Annals of clinical and translational neurologyFree full text
  10. Susceptibility-weighted image features in AQP4-negative-NMOSD versus MS.2024Multiple sclerosis and related disorders
  11. Targeting B cells in neuromyelitis optica spectrum disorder.2024The Lancet. Neurology
  12. Serum neurofilament light chain predicts spinal cord atrophy in neuromyelitis optica spectrum disorder.2023Journal of neuroimmunology
  13. Rituximab induces a transient fluctuation of peripheral and follicular helper T cells in neuromyelitis optica spectrum disorder.2023Journal of neuroimmunology
  14. Bruton's tyrosine kinase-bearing B cells and microglia in neuromyelitis optica spectrum disorder.2023Journal of neuroinflammationFree full text
  15. A real-world study of interleukin-6 receptor blockade in patients with neuromyelitis optica spectrum disorder.2023Journal of neurology
  16. Personalized estimates of morphometric similarity in multiple sclerosis and neuromyelitis optica spectrum disorders.2023NeuroImage. ClinicalFree full text
  17. The prevalence of anti-neurofascin-155 antibodies in patients with neuromyelitis optica spectrum disorders.2021Clinical and experimental immunology
  18. Group 2 innate lymphoid cells suppress the pathology of neuromyelitis optica spectrum disorder.2021FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  19. Early Initiation of Tocilizumab Treatment Against Moderate-to-Severe Myelitis in Neuromyelitis Optica Spectrum Disorder.2021Frontiers in immunologyFree full text
  20. Effects of Tocilizumab Therapy on Circulating B Cells and T Helper Cells in Patients With Neuromyelitis Optica Spectrum Disorder.2021Frontiers in immunologyFree full text
  21. Elevated cerebrospinal fluid β2-microglobulin levels in patients with neuromyelitis optica spectrum disorders.2021Multiple sclerosis and related disorders
  22. Cerebrospinal fluid lactate level in aquaporin-4 antibody positive neuromyelitis optica spectrum disorders: a hint on differential diagnosis and possible immunopathogenesis.2021Multiple sclerosis and related disorders
All its trials on ClinicalTrials.gov, any status15
  1. Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum DisorderRecruitingNCT07420296Lead sponsorPhase 3Start 2026-01
  2. Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune DiseasesRecruitingNCT07022197Lead sponsorPhase 1/Phase 2Start 2025-04
  3. Eculizumab For the Acute Attack of Neuromyelitis Optica Spectrum DisorderActive, not recruitingNCT07184840Lead sponsorPhase 2Start 2025-09
  4. Efficacy and Safety of Ruxolitinib in Neuromyelitis Optica Spectrum DisordersWithdrawnNCT05909943Lead sponsorPhase 1/Phase 2Start 2024-06
  5. Efficacy and Safety of Baricitinib in Neuromyelitis Optica Spectrum DisordersActive, not recruitingNCT05792462Lead sponsorPhase 1Start 2023-04
  6. Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum DisordersActive, not recruitingNCT05403138Lead sponsorPhase 2/Phase 3Start 2022-11
  7. Effects of Ofatumumab Treatment on Immune Cells and Meningeal Lymphatic Drainage in Patients With Demyelinating DiseasesStatus unknownNCT05414487Lead sponsorStart 2022-10
  8. Efficacy and Safety of Belimumab in Neuromyelitis Optica Spectrum DisordersCompletedNCT05154734Lead sponsorPhase 1/Phase 2Start 2021-12
  9. Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum DisordersCompletedNCT03350633Lead sponsorPhase 2/Phase 3Start 2017-11
  10. Efficacy and Safety of Bortezomib as add-on Treatment in Relapsing Neuromyelitis Optica Spectrum DisorderCompletedNCT02893111Lead sponsorPhase 2Start 2015-12
  11. Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum DisordersCompletedNCT02249676Lead sponsorPhase 2Start 2013-01
  12. A Longitudinal Study of ACTEMRA® (Tocilizumab) as Monotherapy in Highly Active NMOSDCompletedNCT03062579Lead (inferred)Phase 1/Phase 2Start 2017-02
  13. A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)RecruitingNCT06413654Study sitePhase 2/Phase 3Start 2024-07
  14. Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD)RecruitingNCT05145361Study siteEarly phase 1Start 2022-04
  15. A Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum DisordersActive, not recruitingNCT06044350Study sitePhase 2Start 2023-08
More papers found outside PubMed (not counted)2
  1. Bone Marrow Granulopoiesis in Neuromyelitis Optica Spectrum Disorder (S32.006)2024Neurologyarticle
  2. Efficacy of mycophenolate mofetil for AQP4 antibody positive optic neuritis immunotherapy2022DOAJ (DOAJ: Directory of Open Access Journals)article

Run the PubMed searchClinicalTrials.gov

Other diseases

IgG4-related disease

IgG4相关性疾病

Led 3 of the 246 English-language PubMed papers on IgG4-related disease with an author in mainland China, 2021–2025: 1.2%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 0020242025: 002025

1 hospital in Tianjin for IgG4-related disease46 hospitals in China for IgG4-related disease

No open trial on IgG4-related disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesDiagnosis & look-alikesTreatment & relapse
Departments in papersGastroenterology / hepatologyRheumatology & immunology

Run the PubMed searchClinicalTrials.gov

Other diseases

Myasthenia gravis

重症肌无力

Led 21 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 4.2%.

Papers led
21
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
4
led by another institution
Papers led per year
2021: 6620212022: 4420222023: 2220232024: 4420242025: 552025

2 hospitals in Tianjin for myasthenia gravis93 hospitals in China for myasthenia gravis

Open trials with this hospital 5

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases
    Phase
    Phase 1/Phase 2
    Started
    2025-04
    Registry
    NCT07022197

    Age 18 years to 60 years (registered criteria)

    Led by Tianjin Medical University General HospitalTianjin

  2. Recruiting
    Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)
    Phase
    Phase 1
    Started
    2025-09
    Registry
    NCT07215650

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesChangchun, Chengdu, Guangzhou, Guiyang, Shanghai, Taiyuan, Tianjin, Zhengzhou

  3. Recruiting
    Myasthenia Gravis Registry in China
    Phase
    Not given
    Started
    2024-02
    Registry
    NCT06241521

    Age not stated (registered criteria)

    Led by Huashan Hospital; 15 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Nanchang, Shanghai, Suzhou, Tianjin, Xi'an, Xuzhou, Zhengzhou

  4. Recruiting
    Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis
    Phase
    Phase 2
    Started
    2022-07
    Registry
    NCT05067348

    Age 18 years to 80 years (registered criteria)

    Led by Tangdu Hospital; 5 listed hospitals as study sitesBeijing, Changsha, Chengdu, Shanghai, Tianjin, Xi'an

  5. Recruiting
    A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
    Phase
    Phase 3
    Started
    2021-07
    Registry
    NCT04951622

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan, Shanghai, Tianjin, Xi'an

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesThymus & thymectomyAntibodies & diagnosisBiologic & complement drugs
Departments in papersNeurology
Papers it led21
  1. The prognosis of MG patients with different thymic pathology: a multicenter retrospective cohort study.2025BMC medicineFree full text
  2. Single-cell atlas reveals heterogeneous response to FcRn blockade in anti-AChR antibody-positive generalised myasthenia gravis.2025Clinical and translational medicineFree full text
  3. Treatment strategy for myasthenia gravis with GAD65-IgG associated neurological disorders: A case report.2025Journal of neuroimmunology
  4. Outcomes in Relation to the Age at Onset in Patients With Myasthenia Gravis.2025Neurology
  5. The role of regulatory B cell/T follicular helper cell balance in thymoma and thymoma-associated myasthenia gravis.2025Scientific reportsFree full text
  6. Responsiveness to Tocilizumab in Anti-Acetylcholine Receptor-Positive Generalized Myasthenia Gravis.2024Aging and diseaseFree full text
  7. Clinical features of COVID-19 infection in patients with myasthenia gravis: a real-world retrospective study.2024Frontiers in public healthFree full text
  8. Serum amyloid A facilitates expansion of CD4+ T cell and CD19+ B cell subsets implicated in the severity of myasthenia gravis patients.2024Journal of neurochemistry
  9. Distribution of multi-level B cell subsets in thymoma and thymoma-associated myasthenia gravis.2024Scientific reportsFree full text
  10. Thymectomy in thymomatous generalized myasthenia gravis: An analysis of the prognosis and risk factors.2023European journal of neurology
  11. TLR4-MyD88-NF-κB signaling imbalances Th17 and Treg cells in thymoma with myasthenia gravis.2023European review for medical and pharmacological sciences
  12. Expression of TRAF6 in peripheral blood B cells of patients with myasthenia gravis.2022BMC neurologyFree full text
  13. Roles of IL-35-producing T and B cells in anti-acetylcholine receptor antibody-positive myasthenia gravis.2022Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  14. Serum irisin levels in patients with myasthenia gravis.2022Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  15. Thymectomy in ocular myasthenia gravis-prognosis and risk factors analysis.2022Orphanet journal of rare diseasesFree full text
  16. Two types of immune infiltrating cells and six hub genes can predict the occurrence of myasthenia gravis in patients with thymoma.2021BioengineeredFree full text
  17. Efficacy and safety of different dosages of rituximab for refractory generalized AChR myasthenia gravis: A meta-analysis.2021Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  18. Increased serum IL-27 concentrations and IL-27-producing cells in MG patients with positive AChR-Ab.2021Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  19. Low-dose rituximab treatment for new-onset generalized myasthenia gravis.2021Journal of neuroimmunology
  20. Imbalance of Th17 and Tregs in thymoma may be a pathological mechanism of myasthenia gravis.2021Molecular immunology
  21. Effects of thymectomy on late-onset non-thymomatous myasthenia gravis: systematic review and meta-analysis.2021Orphanet journal of rare diseasesFree full text
All its trials on ClinicalTrials.gov, any status9
  1. Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune DiseasesRecruitingNCT07022197Lead sponsorPhase 1/Phase 2Start 2025-04
  2. The Specificity, Sensitivity and Clinical Correlation of CBA, RIPA and ELISA in Detecting AChR and MuSK IgG of Myasthenia GravisCompletedNCT05219097Lead sponsorStart 2021-01
  3. Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)RecruitingNCT07215650Study sitePhase 1Start 2025-09
  4. Myasthenia Gravis Registry in ChinaRecruitingNCT06241521Study siteStart 2024-02
  5. Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia GravisRecruitingNCT05067348Study sitePhase 2Start 2022-07
  6. A Study of Nipocalimab Administered to Adults With Generalized Myasthenia GravisRecruitingNCT04951622Study sitePhase 3Start 2021-07
  7. Open-Label Extension of Tocilizumab in Subjects With Generalized Myasthenia GravisStatus unknownNCT05716035Study sitePhase 2/Phase 3Start 2023-04
  8. A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia GravisTerminatedNCT04963270Study sitePhase 3Start 2021-10
  9. A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia GravisActive, not recruitingNCT05070858Study sitePhase 3Start 2021-12

Run the PubMed searchClinicalTrials.gov

Other diseases

Moyamoya disease

烟雾病

Led 2 of the 356 English-language PubMed papers on moyamoya disease with an author in mainland China, 2021–2025: 0.6%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 002025

2 hospitals in Tianjin for moyamoya disease47 hospitals in China for moyamoya disease

No open trial on moyamoya disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesImaging & blood flowStroke & bleeding outcomesChildren
Departments in papersRadiology / nuclear medicineNeurosurgery
Papers it led2
  1. Three-Dimensional Arterial Spin Labeling for the Evaluation of the Cerebral Hemodynamics in Ischemic and Hemorrhagic Moyamoya Disease.2024Cerebrovascular diseases (Basel, Switzerland)
  2. Risk factors of rupture and mortality for intracranial aneurysms associated with moyamoya disease: a multicenter retrospective study.2024Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
More papers found outside PubMed (not counted)1
  1. Impact of superficial temporal artery⁃middle cerebral artery bypass combined with encephalo⁃myo⁃synangiosis on cognitive function in patients with moyamoya disease2022DOAJ (DOAJ: Directory of Open Access Journals)article

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 7 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.7%.

Papers led
7
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 2220212022: 0020222023: 1120232024: 0020242025: 442025

12 hospitals in Tianjin for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
    Phase
    Phase 3
    Started
    2026-09
    Registry
    NCT07687459

    Age 40 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Hohhot, Jinan, Kunming, Nanchang, Nanjing, Nanning, Nanyang, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wenzhou, Wuhan, Xi'an, Xiamen, Xuzhou, Yichang, Yuncheng, Zhengzhou

  2. Recruiting
    A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis
    Phase
    Phase 2
    Started
    2025-11
    Registry
    NCT07121413

    Age 40 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesChengdu, Guangzhou, Hangzhou, Hohhot, Nanchang, Nanjing, Shanghai, Tianjin, Xuzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Papers it led7
  1. Roflumilast mitigates idiopathic pulmonary fibrosis via inhibition of iron accumulation and ferroptosis.2025European journal of pharmacology
  2. The histone demethylase KDM6B links obstructive sleep apnea to idiopathic pulmonary fibrosis.2025FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  3. Identification and validation of CDC20 and ITCH as ubiquitination related biomarker in idiopathic pulmonary fibrosis.2025Hereditas
  4. Add-On Dextromethorphan Improves the Effects of Pirfenidone in Bleomycin-Treated Mice and Patients With Pulmonary Fibrosis.2025Respirology (Carlton, Vic.)
  5. Potential biomarkers for diagnosis and disease evaluation of idiopathic pulmonary fibrosis.2023Chinese medical journal
  6. Identification of autophagy-related genes in idiopathic pulmonary fibrosis using bioinformatics methods.2021Chinese medical journal
  7. Role of various imbalances centered on alveolar epithelial cell/fibroblast apoptosis imbalance in the pathogenesis of idiopathic pulmonary fibrosis.2021Chinese medical journal
All its trials on ClinicalTrials.gov, any status13
  1. Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)RecruitingNCT07687459Study sitePhase 3Start 2026-09
  2. A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary FibrosisRecruitingNCT07121413Study sitePhase 2Start 2025-11
  3. Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary FibrosisNot yet recruitingNCT07131150Study sitePhase 2Start 2025-08
  4. A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With NerandomilastActive, not recruitingNCT06238622Study sitePhase 3Start 2024-09
  5. A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary FibrosisTerminatedNCT06360094Study sitePhase 2Start 2024-08
  6. A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT06335303Study sitePhase 2Start 2024-09
  7. Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary FibrosisTerminatedNCT06097260Study sitePhase 2Start 2023-11
  8. Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT05938920Study sitePhase 2Start 2023-06
  9. A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT05321069Study sitePhase 3Start 2022-10
  10. A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary FibrosisTerminatedNCT04552899Study sitePhase 3Start 2021-03
  11. A Study to Evaluate Long Term Safety and Efficacy of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary FibrosisTerminatedNCT04594707Study sitePhase 3Start 2021-08
  12. Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)TerminatedNCT04419558Study sitePhase 3Start 2020-09
  13. Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)TerminatedNCT03955146Study sitePhase 3Start 2019-06

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 1 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

5 hospitals in Tianjin for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmology
Papers it led1
  1. DNA nanoflower Oligo-PROTAC for targeted degradation of FUS to treat neurodegenerative diseases.2025Nature communications
Earlier papers (2016–2020)3
  1. Triple Stimulation Technique in Amyotrophic Lateral Sclerosis.2019Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society
  2. Neurofilament Subunit L Levels in the Cerebrospinal Fluid and Serum of Patients with Amyotrophic Lateral Sclerosis.2018Neuro-degenerative diseases
  3. The emerging link between O-GlcNAcylation and neurological disorders.2017Cellular and molecular life sciences : CMLS

Run the PubMed searchClinicalTrials.gov

Other diseases

Spinal muscular atrophy

脊髓性肌萎缩症

Led 1 of the 55 English-language PubMed papers on spinal muscular atrophy with an author in mainland China, 2021–2025: 1.8%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

1 hospital in Tianjin for spinal muscular atrophy51 hospitals in China for spinal muscular atrophy

No open trial on spinal muscular atrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led1
  1. Pregnancy and delivery in a woman with spinal muscular atrophy type III.2025European journal of obstetrics, gynecology, and reproductive biology

Run the PubMed searchClinicalTrials.gov

Other diseases

Duchenne muscular dystrophy

杜氏肌营养不良

Led 2 of the 213 English-language PubMed papers on Duchenne muscular dystrophy with an author in mainland China, 2021–2025: 0.9%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 002025

4 hospitals in Tianjin for Duchenne muscular dystrophy116 hospitals in China for Duchenne muscular dystrophy

No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicineNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Alport syndrome

Alport 综合征

Led 1 of the 58 English-language PubMed papers on Alport syndrome with an author in mainland China, 2021–2025: 1.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

1 hospital in Tianjin for Alport syndrome60 hospitals in China for Alport syndrome

No open trial on Alport syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 10 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 1.4%.

Papers led
10
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 4420232024: 2220242025: 222025

6 hospitals in Tianjin for IgA nephropathy346 hospitals in China for IgA nephropathy

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular Diseases
    Phase
    Phase 2
    Started
    2026-05
    Registry
    NCT07614477

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Tianjin

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersNephrology
Papers it led10
  1. The neutrophil-to-monocyte ratio: a superior inflammatory marker predicting poor prognosis in IgA nephropathy.2025BMC nephrology
  2. Increased soluble CD16b derived from activated neutrophils in plasma is associated with the pathogenesis and progression of IgA nephropathy.2025International immunopharmacology
  3. Clinical and pathological findings of IgA nephropathy following SARS-CoV-2 infection.2024Clinical and experimental medicine
  4. Prognosis of IgA Nephropathy with Stages 3b-5 CKD.2024Kidney & blood pressure research
  5. The effect of fibrinoid necrosis on the clinical features and outcomes of primary IgA nephropathy.2023BMC nephrology
  6. Deciphering prognostic value of CD22 and its contribution to suppression of proinflammatory cytokines production in patients with IgA nephropathy.2023Immunology letters
  7. Effect of hematuria on the kidney disease progression in IgA nephropathy patients with mild proteinuria and well-preserved renal function.2023International immunopharmacology
  8. Circulating platelets supply ST6Gal-1 in patients with IgA nephropathy.2023Postgraduate medicine
  9. The difference between patients with nephrotic syndrome and nephrotic-range proteinuria in IgA nephropathy: a propensity score matched cohort study.2022BMC nephrology
  10. Sialylation of IgG inhibits the formation of galactose-deficient IgA1-containing immune complexes and protects mesangial cells from injury in IgA nephropathy.2022BMC nephrology
Earlier papers (2016–2020)9
  1. A case presentation of an IgA nephropathy patient with Vogt-Koyanagi-Harada syndrome.2020BMC nephrology
  2. C1GALT1 expression is associated with galactosylation of IgA1 in peripheral B lymphocyte in immunoglobulin a nephropathy.2020BMC nephrology
  3. ST6Gal1 is up-regulated and associated with aberrant IgA1 glycosylation in IgA nephropathy: An integrated analysis of the transcriptome.2020Journal of cellular and molecular medicine
  4. ELL2 Is Downregulated and Associated with Galactose-Deficient IgA1 in IgA Nephropathy.2019Disease markers
  5. Comprehensive analysis of aberrantly expressed profiles of mRNA and its relationship with serum galactose-deficient IgA1 level in IgA nephropathy.2019Journal of translational medicine
  6. Clinical Significance of Galactose-Deficient IgA1 by KM55 in Patients with IgA Nephropathy.2019Kidney & blood pressure research
  7. Changes E3 ubiquitin protein ligase 1 gene mRNA expression correlated with IgA1 glycosylation in patients with IgA nephropathy.2019Renal failure
  8. Corticosteroid for IgA Nephropathy: Are They Really Therapeutic?2018American journal of nephrology
  9. A Systematic Review and Meta-Analysis of Kidney and Pregnancy Outcomes in IgA Nephropathy.2016American journal of nephrology
All its trials on ClinicalTrials.gov, any status2
  1. Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular DiseasesRecruitingNCT07614477Study sitePhase 2Start 2026-05
  2. A Study of Telitacicept for IgA Nephropathy (TELIGAN)Active, not recruitingNCT05799287Study sitePhase 3Start 2023-04

Run the PubMed searchClinicalTrials.gov

Other diseases

Osteogenesis imperfecta

成骨不全症

Led 4 of the 99 English-language PubMed papers on osteogenesis imperfecta with an author in mainland China, 2021–2025: 4.0%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 2220242025: 002025

2 hospitals in Tianjin for osteogenesis imperfecta59 hospitals in China for osteogenesis imperfecta

No open trial on osteogenesis imperfecta lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led 7 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 2.3%.

Papers led
7
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
3
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 2220242025: 332025

5 hospitals in Tianjin for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
    Phase
    Phase 3
    Started
    2025-12
    Registry
    NCT07282353

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBaoji, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Hangzhou, Harbin, Hefei, Linyi, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Shiyan, Taizhou, Tianjin, Xi'an, Xiamen, Zhanjiang, Zhengzhou

  2. Recruiting
    Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis
    Phase
    Phase 2/Phase 3
    Started
    2023-02
    Registry
    NCT05749822

    Age 18 years to 75 years (registered criteria)

    Led by Xijing Hospital; 11 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Kunming, Nanjing, Shenyang, Tianjin, Xi'an, Yan’an, Zhengzhou

  3. Recruiting
    Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis
    Phase
    Phase 3
    Started
    2023-02
    Registry
    NCT05751967

    Age 18 years to 75 years (registered criteria)

    Led by Xijing Hospital; 6 listed hospitals as study sitesChengdu, Guangzhou, Lanzhou, Nanjing, Shenyang, Tianjin, Xi'an

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersGastroenterology / hepatology
Papers it led7
  1. The Depletion of Plasma Cells but Not CD20+B Cells Alleviates Primary Biliary Cholangitis.2025Liver international : official journal of the International Association for the Study of the Liver
  2. Characterisation and Clinical Relevance of Tertiary Lymphoid Structures in Primary Biliary Cholangitis.2025Liver international : official journal of the International Association for the Study of the Liver
  3. Lactococcus garvieae aggravates cholestatic liver disease by increasing intestinal permeability and enhancing bile acid reabsorption.2025World journal of gastroenterology
  4. Associations between sleep disorders and clinical outcomes of patients with primary biliary cholangitis.2024Advances in medical sciences
  5. Depressive symptom as a risk factor for cirrhosis in patients with primary biliary cholangitis: Analysis based on Lasso-logistic regression and decision tree models.2024Brain and behavior
  6. Anti-gp210-positive primary biliary cholangitis: The dilemma of clinical treatment and emerging mechanisms.2023Annals of hepatology
  7. Novel HLA-DRB1 alleles contribute risk for disease susceptibility in primary biliary cholangitis.2022Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
Chinese-language papers (not in the count)2
  1. [Clinical characteristics and risk factors for disease progression in patients with anti-gp210 antibody-positive primary biliary cholangitis].2025Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
  2. [Research progress on clinical features and pathogenesis of anti-gp210-positive primary biliary cholangitis].2024Zhonghua nei ke za zhi
Earlier papers (2016–2020)2
  1. [Characteristics of initial diagnosis in autoimmune liver disease: an 18-year, retrospective single-center study].2019Zhonghua nei ke za zhi
  2. miR-181a regulates Th17 cells distribution via up-regulated BCL-2 in primary biliary cholangitis.2018International immunopharmacology
All its trials on ClinicalTrials.gov, any status3
  1. A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCARecruitingNCT07282353Study sitePhase 3Start 2025-12
  2. Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary CholangitisRecruitingNCT05749822Study sitePhase 2/Phase 3Start 2023-02
  3. Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary CholangitisRecruitingNCT05751967Study sitePhase 3Start 2023-02

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary sclerosing cholangitis

原发性硬化性胆管炎

Led 1 of the 100 English-language PubMed papers on primary sclerosing cholangitis with an author in mainland China, 2021–2025: 1.0%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

2 hospitals in Tianjin for primary sclerosing cholangitis90 hospitals in China for primary sclerosing cholangitis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis
    Phase
    Phase 3
    Started
    2026-05
    Registry
    NCT07387549

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changchun, Guangzhou, Jinan, Nanchang, Shanghai, Tianjin, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersGastroenterology / hepatologySurgery (general/hepatobiliary/pancreatic)

Run the PubMed searchClinicalTrials.gov

Other diseases

Hirschsprung disease

先天性巨结肠

Led no English-language PubMed papers on Hirschsprung disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Tianjin for Hirschsprung disease82 hospitals in China for Hirschsprung disease

No open trial on Hirschsprung disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Familial adenomatous polyposis

家族性腺瘤性息肉病

Led no English-language PubMed papers on familial adenomatous polyposis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Tianjin for familial adenomatous polyposis76 hospitals in China for familial adenomatous polyposis

No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Leber hereditary optic neuropathy

Leber 遗传性视神经病变

Led 3 of the 52 English-language PubMed papers on Leber hereditary optic neuropathy with an author in mainland China, 2021–2025: 5.8%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 0020222023: 1120232024: 0020242025: 002025

1 hospital in Tianjin for Leber hereditary optic neuropathy32 hospitals in China for Leber hereditary optic neuropathy

No open trial on Leber hereditary optic neuropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

天津医科大学总医院

Tianjin Medical University General Hospital

天津

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look at the hospital's own pages linked above.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR Wikidata
General Hospital of Tianjin Medical University; Tianjin General Hospital; Tianjin Medical University General Hospital Airport Site; Binhai Hospital of Tianjin Medical University General Hospital; Tianjin Medical University General HospitalTianjinP.R. China; Tianjin Medical University General Hospital Airport Hospital; Tianjin Medical University General hospital; Tianjin Medical University General Hospital Hospital

Suggest a correctionDownload the data